Key result
tPA remains preferred for acute ischemic stroke, while aspirin offers a safer alternative for minor strokes.
Why the study?
The optimal choice between tPA and aspirin for stroke treatment requires balancing stroke severity and timing against potential complications.
The choice between tPA and aspirin for acute ischemic stroke depends on stroke severity and timing, balancing the efficacy of timely tPA against the lower complication profile of aspirin in minor strokes.
Supports severity- and time-based stroke treatment selection; leaves open precise thresholds for prospective validation.
The choice between tPA and aspirin for stroke treatment depends on stroke severity and timing, with tPA generally preferred for timely treatment of acute ischemic stroke, while aspirin is a safer alternative with fewer complications, especially for minor strokes.
No takes yet. Share an insight, caveat, or question.
Tripdatabase (2026) studied this question. Tissue plasminogen activator (tPA) is generally preferred for timely treatment of acute ischemic stroke, whereas aspirin is a safer alternative with fewer complications for minor strokes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: